NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free NPCE Stock Alerts $14.01 +0.01 (+0.07%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$13.60▼$14.5150-Day Range$12.37▼$17.5052-Week Range$3.80▼$18.15Volume152,876 shsAverage Volume107,027 shsMarket Capitalization$368.18 millionP/E RatioN/ADividend YieldN/APrice Target$15.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get NeuroPace alerts: Email Address NeuroPace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside12.3% Upside$15.67 Price TargetShort InterestHealthy0.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 8 Articles This WeekInsider TradingSelling Shares$6.97 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.14) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector459th out of 910 stocksSurgical & Medical Instruments Industry52nd out of 95 stocks 3.4 Analyst's Opinion Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuroPace has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.73% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroPace has recently increased by 177.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NPCE. Previous Next 1.9 News and Social Media Coverage News SentimentNeuroPace has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for NeuroPace this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for NPCE on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. This is a decrease of -73% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,968,331.00 in company stock.Percentage Held by Insiders27.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NeuroPace are expected to decrease in the coming year, from ($1.14) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -10.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -10.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 17.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Bull ReportHealthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.Click here to see why this small company is trusted by the Mayo Clinic About NeuroPace Stock (NASDAQ:NPCE)NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Read More NPCE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NPCE Stock News HeadlinesApril 19, 2024 | insidertrades.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 2,623 Shares of StockApril 16, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in StockApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 20, 2024 | investing.comOrbiMed Advisors sells shares in NeuroPace worth over $238,000April 20, 2024 | americanbankingnews.comOrbimed Advisors Llc Sells 2,623 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockApril 20, 2024 | americanbankingnews.comOrbimed Advisors Llc Sells 14,069 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockApril 17, 2024 | globenewswire.comNeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024April 16, 2024 | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 461,899 SharesApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 15, 2024 | americanbankingnews.comHead-To-Head Analysis: NeuroPace (NASDAQ:NPCE) and Akili (NASDAQ:AKLI)April 14, 2024 | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 10, 2024 | fool.comNeuroPace (NASDAQ: NPCE)April 4, 2024 | msn.com'Biggest mistake' bond investors may make ahead of Fed rate cutsMarch 27, 2024 | globenewswire.comNeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceMarch 13, 2024 | markets.businessinsider.comThe Latest Analyst Ratings For NeuroPaceMarch 7, 2024 | markets.businessinsider.comNeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth DriversMarch 7, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNeuroPace Full Year 2023 Earnings: EPS Beats ExpectationsMarch 7, 2024 | seekingalpha.comNeuroPace, Inc. (NPCE) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | benzinga.comRecap: NeuroPace Q4 EarningsMarch 6, 2024 | msn.comNeuroPace GAAP EPS of -$0.23March 6, 2024 | markets.businessinsider.comNeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending ConcernsMarch 5, 2024 | globenewswire.comNeuroPace Announces Record Full Year 2023 Revenue of $65.4 MillionMarch 5, 2024 | investorplace.comFinancial Freedom Fighters: 3 Stocks to Liberate Your PortfolioFebruary 24, 2024 | msn.comNeuroPace (NPCE) Price Target Increased by 27.95% to 15.01February 22, 2024 | benzinga.comA Glimpse Into The Expert Outlook On NeuroPace Through 4 AnalystsFebruary 22, 2024 | benzinga.comNeuroPace Stock (NASDAQ:NPCE) Earnings Dates and Earning CallsSee More Headlines Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/23/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NPCE CUSIPN/A CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees171Year FoundedN/APrice Target and Rating Average Stock Price Target$15.67 High Stock Price Target$22.00 Low Stock Price Target$9.00 Potential Upside/Downside+9.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,960,000.00 Net Margins-50.38% Pretax Margin-50.38% Return on Equity-153.76% Return on Assets-31.73% Debt Debt-to-Equity Ratio2.76 Current Ratio5.71 Quick Ratio5.02 Sales & Book Value Annual Sales$65.42 million Price / Sales5.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book18.15Miscellaneous Outstanding Shares26,280,000Free Float19,056,000Market Cap$376.86 million OptionableOptionable Beta2.09 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Martha J. Morrell (Age 67)Chief Medical Officer Comp: $555.87kMr. Joel D. Becker (Age 56)CEO, President & Director Ms. Rebecca L. Kuhn (Age 63)CFO, VP of Finance & Administration and Assistant Secretary Comp: $440.92kMs. Kelley NicholasVice President of SalesMs. Irene Thomas (Age 55)Vice President of Human Resources Key CompetitorsBioventusNYSE:BVSSurmodicsNASDAQ:SRDXAnika TherapeuticsNASDAQ:ANIKCVRxNASDAQ:CVRXTactile Systems TechnologyNASDAQ:TCMDView All CompetitorsInsiders & InstitutionsOrbimed Advisors LlcSold 2,623 sharesTotal: $36,879.38 ($14.06/share)Orbimed Advisors LlcSold 14,069 sharesTotal: $197,106.69 ($14.01/share)Orbimed Advisors LlcSold 461,899 sharesTotal: $6.69 M ($14.49/share)Kent Lake Capital LLCBought 96,529 shares on 2/14/2024Ownership: 2.553%Martha MorrellSold 1,923 sharesTotal: $28,998.84 ($15.08/share)View All Insider TransactionsView All Institutional Transactions NPCE Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroPace stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NPCE shares. View NPCE analyst ratings or view top-rated stocks. What is NeuroPace's stock price target for 2024? 7 brokers have issued 12 month target prices for NeuroPace's shares. Their NPCE share price targets range from $9.00 to $22.00. On average, they predict the company's stock price to reach $15.67 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View analysts price targets for NPCE or view top-rated stocks among Wall Street analysts. How have NPCE shares performed in 2024? NeuroPace's stock was trading at $10.31 at the beginning of 2024. Since then, NPCE shares have increased by 35.3% and is now trading at $13.95. View the best growth stocks for 2024 here. Are investors shorting NeuroPace? NeuroPace saw a increase in short interest in March. As of March 31st, there was short interest totaling 85,900 shares, an increase of 178.0% from the March 15th total of 30,900 shares. Based on an average daily trading volume, of 98,900 shares, the short-interest ratio is currently 0.9 days. Currently, 0.7% of the shares of the stock are short sold. View NeuroPace's Short Interest. When is NeuroPace's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NPCE earnings forecast. How can I listen to NeuroPace's earnings call? NeuroPace will be holding an earnings conference call on Wednesday, May 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) posted its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.10. The company had revenue of $18.01 million for the quarter, compared to the consensus estimate of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative trailing twelve-month return on equity of 153.76%. What ETF holds NeuroPace's stock? iShares Neuroscience and Healthcare ETF holds 788 shares of NPCE stock, representing 0.32% of its portfolio. What guidance has NeuroPace issued on next quarter's earnings? NeuroPace updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $73.0 million-$77.0 million, compared to the consensus revenue estimate of $74.6 million. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NPCE) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTIMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
